Have you seen any spicy takes on LinkedIn?
How will we look back on Emma Walmsley's tenure as GSK's CEO? Why did one of the FDA's top drug officials call out an obscure lupus drug on LinkedIn? And will we ever stop talking about the pharma patent cliff? We discuss all that and more on this week's episode of "The Readout LOUD," a weekly biotech podcast from STAT. Adam is out this week, so Allison and Elaine dive into the latest news, starting with another biotech acquisition and a new CEO at GSK. Then, they invite health policy researcher Stacie Dusetzina to break down President Trump's "most-favored nation" pricing deal with Pfizer. LISTEN NOW Subscribe to the podcast on Apple Podcasts or Spotify to never miss an episode Visit the archive to see past episodes |
|
| STAT, 1 Exchange Place, Boston, MA | ©2025, All Rights Reserved. | |
|
No comments